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Key messages
What is already known about this subject?
 ► Primary efficacy data from the phase iiiB/iV study 
Oral Strategy in patients with rheumatoid arthritis 
(ra) supported a preference for adding tofacitinib 
to methotrexate (MtX) rather than switching to 
tofacitinib monotherapy, which has shown efficacy 
versus placebo.
 ► improvements in patient-reported outcomes (PrOs) 
are a priority for patients with ra.
What does this study add?
 ► Using data from Oral Strategy, this analysis is 
the first adequately powered direct comparison 
of PrOs associated with tofacitinib monotherapy, 
tofacitinib+MtX and adalimumab (aDa)+MtX.
 ► tofacitinib+MtX, aDa+MtX and tofacitinib mono-
therapy improved PrOs in patients with ra and an 
inadequate response to MtX; improvements were 
generally greater with both combination arms than 
with monotherapy.
How might this impact on clinical practice?
 ► these data show that tofacitinib administered as 
monotherapy is a suitable treatment for patients 
with a previous inadequate response to MtX, al-
though combination therapy remains the most ef-
fective treatment strategy.
ABSTRACT
Objective to provide the first direct comparison of 
patient-reported outcomes (PrOs) following treatment with 
tofacitinib monotherapy versus tofacitinib or adalimumab 
(aDa) in combination with methotrexate (MtX) in patients 
with rheumatoid arthritis (ra) with inadequate response to 
MtX (MtX-ir).
Methods Oral Strategy (nct02187055), a phase iiiB/
iV, head-to-head, randomised controlled trial, assessed 
non-inferiority between tofacitinib 5 mg two times per day 
monotherapy, tofacitinib 5 mg two times per day+MtX and 
aDa 40 mg every other week+MtX. PrOs assessed included 
the following: Patient global assessment of disease activity 
(Ptga), Pain, Health assessment Questionnaire-Disability index, 
Functional assessment of chronic illness therapy-Fatigue 
and 36-item Short-Form Health Survey (SF-36) summary and 
domain scores.
Results Substantial improvements from baseline were 
reported across all PrOs in all treatment arms, which, in 
the majority, met or exceeded minimum clinically important 
differences. compared with tofacitinib monotherapy, 
tofacitinib+MtX combination treatment conferred significantly 
greater improvements in Ptga, Pain and SF-36 physical 
component summary scores at month 6. Statistically or 
numerically greater improvements were often, but not 
uniformly, reported for combination treatments compared with 
tofacitinib monotherapy at other time points.
Conclusion treatment with tofacitinib+MtX, aDa+MtX 
and tofacitinib monotherapy resulted in clinically 
meaningful improvements in PrOs in MtX-ir patients with 
ra. these were comparatively greater with combination 
treatments versus tofacitinib monotherapy, although 
differences between treatment arms were small, limiting 
our ability to confer clinical meaning.
Trial registration number nct02187055.
InTROduCTIOn
Rheumatoid arthritis (RA) is a chronic and 
debilitating autoimmune disease characterised 
by systemic inflammation, persistent synovitis 
and joint destruction, and affects approxi-
mately 0.24% of the global population.1
When patients with RA are inadequate 
responders (IR) to conventional synthetic 
disease-modifying antirheumatic drugs 
(csDMARDs) such as methotrexate (MTX), 
the next treatment step is either to switch or 
add therapies.2 3 First-choice add-on therapies 
include biologic DMARDs (bDMARDS), usually 
tumour necrosis factor inhibitors (TNFi), and 
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Janus kinase inhibitors, all approved in RA.2 4 The TNFi 
adalimumab (ADA) is a recombinant human monoclonal 
antibody applied at 40 mg every other week (Q2W), with 
demonstrated efficacy in MTX-IR patients with active 
RA5–12 and an acceptable safety profile in long-term exten-
sion studies of over 10 years' duration.13 The efficacy and 
safety of the oral Janus kinase inhibitor tofacitinib 5 mg 
and 10 mg two times per day administered as monotherapy 
or in combination with csDMARDs in patients with active 
RA have been demonstrated in phase III14–24 randomised 
controlled trials (RCTs) of up to 24 months’ duration, and 
in long-term extension studies with as long as 9.5 years of 
observation.25–27
ORAL Strategy (NCT02187055) was a head-to-head, 
phase IIIB/IV RCT that directly compared the efficacy 
and safety of tofacitinib monotherapy, tofacitinib in combi-
nation with MTX and ADA in combination with MTX 
in MTX-IR patients with active RA.28 In this trial, Amer-
ican College of Rheumatology 50% (ACR50) responses 
at month 6 (primary endpoint) were achieved by 38% of 
patients receiving tofacitinib monotherapy, 46% receiving 
tofacitinib+MTX and 44% receiving ADA+MTX. At month 
6, tofacitinib+MTX was non-inferior to ADA+MTX; the 
non-inferiority of tofacitinib monotherapy relative to either 
combination therapy was inconclusive. Rates of remission 
and low disease activity were numerically similar between 
the three treatment arms, no new or unexpected safety 
issues were observed, and overall adverse event rates and 
discontinuations due to adverse events were similar between 
combination and monotherapy arms.
Improvements in pain, physical function, fatigue 
and overall health-related quality of life (HRQoL) are 
a priority for patients and, in accordance with clin-
ical guidelines, treatment decisions should be shared 
between rheumatologists and patients.2 3 Treatment with 
tofacitinib or ADA in combination with MTX has previ-
ously demonstrated improvements versus placebo across 
patient-reported outcomes (PROs) in the phase III ORAL 
Standard RCT of MTX-IR patients with moderately to 
severely active RA; however, this trial was not powered 
for direct comparisons between active treatment arms.22 
Here, we present the first adequately powered direct 
comparison of PROs associated with tofacitinib mono-
therapy, tofacitinib+MTX and ADA+MTX in the ORAL 
Strategy RCT.
MeTHOds
study design
ORAL Strategy was a 1-year, triple-dummy, active compar-
ator head-to-head RCT (see online supplementary figure 
S1, available at RMD Open online, for the study design). It 
was conducted in accordance with the International Ethical 
Guidelines for Biomedical Research Involving Human 
Subjects, the Declaration of Helsinki and the Good Clin-
ical Practice Guidelines, along with applicable local regula-
tory requirements and laws. All patients provided written, 
informed consent.
Randomisation and treatment
Patients were randomised 1:1:1 in a blinded fashion to 
receive tofacitinib monotherapy, tofacitinib+MTX or 
ADA+MTX. Oral tofacitinib was dosed at 5 mg two times 
per day and subcutaneous ADA was dosed at 40 mg Q2W. 
All patients were required to have been treated for ≥4 
months with MTX at a stable dosage of 15–25 mg/week 
for ≥6 weeks prior to baseline (MTX doses <15 mg/week 
were permitted if intolerance/toxicity to higher doses 
was documented). Further details of the randomisation 
procedures are provided in the primary publication.28
Patients
Patient inclusion and exclusion criteria are provided in 
the primary publication.28 Briefly, eligible patients were 
≥18 years of age and met ACR/European League Against 
Rheumatism classification criteria for active RA.29 They 
were required to discontinue all csDMARDs except MTX 
for ≥4 weeks or five half-lives, whichever was longer, prior 
to baseline, but could continue to receive stable non-ste-
roidal anti-inflammatory drugs, analgesics and/or ≤10 mg 
prednisone or equivalent per day throughout the trial. Prior 
TNFi use was not allowed if patients had failed any for either 
lack of efficacy or a related adverse event.
Assessments
Reported PROs included least squares mean (LSM) changes 
from baseline in the following: Patient Global Assessment 
of disease activity (PtGA), arthritis pain (Pain), Health 
Assessment Questionnaire-Disability Index (HAQ-DI), 
Functional Assessment of Chronic Illness Therapy-Fatigue 
(FACIT-F) and 36-Item Short-Form Health Survey version 
2 (SF-36), physical component summary (PCS) and mental 
component summary (MCS) and domain scores (Physical 
Functioning [PF], Role Physical [RP], Bodily Pain [BP], 
General Health, Vitality [VT], Social Functioning, Role 
Emotional and Mental Health). Details of PRO measures 
are in online supplementary figure S1, available at RMD 
Open online.
The proportions of patients reporting improvements 
≥minimum clinically important differences (MCIDs) in 
PtGA, Pain, HAQ-DI, FACIT-F and SF-36 summary and 
domain scores are reported, as well as those reporting 
scores in HAQ-DI, FACIT-F and SF-36 domains within 
normative values. MCIDs have been defined previously 
as follows: ≥10 mm decreases from baseline in PtGA and 
Pain,30 ≥0.22-point decrease from baseline in HAQ-DI 
score,31 ≥4-point increase in FACIT-F score,31 and 
increases from baseline ≥2.5 points in SF-36 PCS and 
MCS and ≥5 points in SF-36 domain (0–100) scores.31 
Normative values for HAQ-DI are ≤0.2532 and norma-
tive values for FACIT-F have been reported as ≥40.133 
or, more recently, ≥43.534; we also report functional 
remission as previously defined by a HAQ-DI value of 
<0.5.35
Normative values for SF-36 domain scores (see online 
supplementary table S1, available at RMD Open online) 
are based on age-matched and gender-matched norms 
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reported in the SF-36 Scoring Manual36 37 according to 
the population enrolled in ORAL Strategy. The propor-
tions of patients reporting Pain scores <20 mm38–40 
(considered to represent mild pain41), and ≥20% (mild), 
≥30% (moderate), ≥50% (substantial) and ≥70% (exten-
sive) improvements in Pain,38–40 are also reported.
statistical analyses
All PRO analyses were based on the full analysis set (all 
patients randomised who received ≥1 dose of study drug 
[tofacitinib or ADA]). Descriptive statistics were provided 
for baseline and scheduled post-baseline measurements 
(month 0, week 6 [except SF-36 and FACIT-F endpoints], 
and months 3, 6, 9 and 12). Analysis of continuous data 
(eg, change from baseline in HAQ-DI) was conducted 
using a mixed-effects model of repeated measures, with 
fixed effects including treatment, geographical region, 
visit and treatment-by-visit interaction, and baseline 
as a covariate. This approach implicitly imputes any 
missing values. Binary variables (eg, % patients reporting 
improvements ≥MCIDs) were compared using the 
normal approximation to the binomial distribution. For 
this approach, missing values were ignored and response 
rates were calculated for patients with non-missing values 
at that visit. Analyses included 95% confidence intervals 
(CIs). Statistical significance was set at ≤0.05 with no 
correction for multiple comparisons. Statistically signif-
icant results are only reported in the text if present at ≥2 
time points (months), or at an early time point, that is, 
at week 6 and/or month 3. SF-36 domain scores at base-
line and scores at months 0, 3, 6, 9 and 12 (mean values 
expressed on the 0–100 scale) are displayed using spyder-
grams, where higher scores indicate improved HRQoL.
Statistical analyses not prespecified in the study statistical 
analysis protocol were as follows: descriptive statistics of 
baseline Pain, PtGA, HAQ-DI, FACIT-F and SF-36 summary 
scores; descriptive statistics of baseline and post-baseline 
SF-36 domain scores; age/gender adjustments of norms 
for domain scores used in the construction of the spyder-
grams; rates (and statistical tests) of reported improve-
ments ≥MCID; reported scores within normative values; 
reported scores below function remission for HAQ-DI; and 
reported 20%, 30%, 50% and 70% improvements in Pain 
scores, and the percentage achieving a target Pain score of 
<20 mm. The statistical tests are comparisons of rates using 
the normal approximation to the binomial, with differ-
ences and 95% CIs formed.
ResulTs
Patients
In all, 1152 patients were randomised at 194 centres 
worldwide (located in North America, Latin America, 
Europe, the Middle East, Africa and the Asia-Pacific 
region), of whom 1146 were included in the full analysis 
set (tofacitinib monotherapy, n=384; tofacitinib+MTX, 
n=376; ADA+MTX, n=386). Patient disposition and base-
line disease and demographic characteristics are included 
in the primary publication.28 Key baseline disease 
characteristics included the following: mean disease 
duration from 7.5 to 8.4 years; mean (standard deviation 
[SD]) tender joint counts (28-joint count) from 15.2 
(6.7) to 15.6 (6.5); mean swollen joint counts (28-joint 
count) from 11.0 (5.4) to 11.8 (5.7); and mean (SD) 
Disease Activity Scores 28–4 using erythrocyte sedimen-
tation rate from 6.5 (0.9) to 6.6 (0.9). A similar propor-
tion of patients in each treatment arm completed the 
trial (tofacitinib monotherapy, n=315 [82.0%]; tofacitin-
ib+MTX, n=303 [80.6%]; ADA+MTX, n=312, [80.8%]), 
with comparable reasons for discontinuation.28
PROs at baseline
Baseline PROs were similar between treatment arms 
(table 1). Mean scores ranged from 60.1 to 61.7 for PtGA, 
60.6 to 61.2 for Pain, 1.6 for HAQ-DI (all groups), 26.2 to 
27.1 for FACIT-F, 31.7 to 32.4 for SF-36 PCS and 38.8 to 
39.8 for SF-36 MCS, indicating the substantial impact of 
disease on patients across all parameters.
PROs over time
Substantial improvements from baseline were reported 
across all PROs across all treatment arms (figure 1A–F), 
and the majority of patients reported improvements 
≥MCID (figure 2A–F).
Ptga
Clinically meaningful improvements from baseline were 
reported across all treatment groups at week 6 (tofac-
itinib monotherapy LSM change, –26.1; tofacitinib+MTX, 
–28.2; ADA+MTX, –26.6). At month 3, these approximated 
maximal values were greater with tofacitinib+MTX versus 
monotherapy (p<0.05) (figure 1A). Greater improvements 
from baseline in PtGA were reported in both combination 
arms versus tofacitinib monotherapy at month 6 (tofac-
itinib monotherapy LSM change, –35.7; tofacitinib+MTX, 
–38.4; ADA+MTX, –38.8; both comparisons, p<0.05), which 
were sustained through to month 9 (p<0.05) and month 12 
(p<0.01) (table 1; figure 1A). The proportions of patients 
reporting improvements ≥MCID were similar between all 
treatment arms at all time points (ranges: 71%–77% at 
month 3, 72%–76% at month 6, 72%–78% at month 9 and 
73%–79% at month 12) (figure 2A).
arthritis pain
Clinically meaningful improvements in Pain were reported 
across all treatment groups at week 6 (tofacitinib mono-
therapy LSM change, –22.6; tofacitinib+MTX, –22.8; 
ADA+MTX, –23.0), which generally approached maximal 
values by month 3 (figure 1B). Tofacitinib+MTX resulted 
in greater improvements from baseline versus tofacitinib 
monotherapy at month 3 (p<0.01), and this was sustained 
at month 6 (tofacitinib LSM change, –26.6; tofacitin-
ib+MTX, –30.7; ADA+MTX, –28.1; p<0.05) and month 
12 (p<0.05) (table 1; figure 1B). Greater improvements 
from baseline with ADA+MTX were reported versus tofac-
itinib monotherapy at month 3 (p<0.05) and again at 
month 9 (p<0.05) (figure 1B). The proportions of patients 
reporting improvements ≥MCID were similar between all 
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Table 1 Baseline patient-reported outcomes and changes from baseline at month 6 (FAS)
Baseline, mean (SE) score LSM changes from baseline (±SE) at month 6
Tofacitinib
5 mg two times 
per day
(n=384)
Tofacitinib
5 mg two times 
per day+MTX
(n=376)
ADA+MTX
(n=386)
Tofacitinib
5 mg two times 
per day
(n=384)
Tofacitinib
5 mg two times 
per day+MTX
(n=376)
ADA+MTX
(n=386)
PtGA (n=383)
60.1 (1.09)
(n=376)
61.7 (1.14)
(n=383)
60.2 (1.20)
(n=357)
–35.7 (0.98)
(n=346)
–38.4 (0.99)*
(n=348)
–38.8 (0.98)†
Pain (n=383)
61.2 (1.11)
(n=376)
60.7 (1.15)
(n=383)
60.6 (1.15)
(n=357)
–26.6 (1.26)
(n=347)
–30.7 (1.26)*
(n=351)
–28.1 (1.26)
HAQ-DI (n=383)
1.6 (0.03)
(n=376)
1.6 (0.03)
(n=382)
1.6 (0.03)
(n=356)
–0.52 (0.03)
(n=348)
–0.58 (0.03)
(n=350)
–0.54 (0.03)
FACIT-F (n=383)
27.1 (0.52)
(n=376)
26.2 (0.53)
(n=384)
27.1 (0.52)
(n=357)
7.14 (0.50)
(n=348)
7.59 (0.50)‡
(n=352)
6.07 (0.50)
SF-36 PCS (n=381)
32.4 (0.38)
(n=375)
31.7 (0.36)
(n=382)
31.7 (0.38)
(n=355)
6.7 (0.44)
(n=346)
7.9 (0.43)*
(n=349)
7.8 (0.43)
SF-36 MCS (n=381)
39.3 (0.59)
(n=375)
38.8 (0.57)
(n=382)
39.8 (0.58)
(n=355)
5.2 (0.52)
(n=346)
5.7 (0.51)
(n=349)
4.4 (0.51)
*p<0.05 for tofacitinib+MTX versus tofacitinib monotherapy.
†p<0.05 for ADA+MTX versus tofacitinib monotherapy.
‡p<0.05 for tofacitinib+MTX versus ADA+MTX.
ADA, adalimumab; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; FAS, full analysis set; HAQ-DI, Health Assessment 
Questionnaire-Disability Index; LSM, least squares mean; MCS, mental component summary; MTX, methotrexate; Pain, arthritis pain; PCS, 
physical component summary; PtGA, Patient Global Assessment of disease activity; SE, standard error; SF-36, 36-Item Short-Form Health 
Survey.
treatment arms at all time points (ranges: 71%–76% at 
month 3, 73%–78% at month 6, 74%–80% at month 9 and 
76%–78% at month 12) (figure 2B).
As many as 45% of patients reported Pain scores <20 
mm in any treatment arm at any time point, with greater 
proportions in both combination arms (tofacitinib+MTX 
[p<0.01] and ADA+MTX [p<0.05]) at month 3 versus 
tofacitinib monotherapy (figure 3A).
The majority of patients reported ≥20% (all >69%) or 
≥30% improvements in Pain (all >59%). The proportions 
of patients reporting ≥30% improvements in Pain were 
greater in both combination arms (tofacitinib+MTX and 
ADA+MTX) at month 3 (both p<0.01), and with tofaci-
tinib+MTX at month 6 (p<0.05), versus tofacitinib mono-
therapy (figure 3B).
HaQ-Di
No statistically significant differences in LSM changes 
from baseline in HAQ-DI between treatment arms were 
reported at any time point, with improvements generally 
approaching maximal values by month 3 and continuing 
to month 12 for all treatments (table 1; figure 1C). In 
all treatment arms, the majority of patients reported 
improvements ≥MCID (figure 2C; all >68%). Scores 
≤normative HAQ-DI values ranged from 17% to 25%, 
and scores below functional remission (<0.5 HAQ-DI) 
ranged from 19% to 32% (online supplementary table 
S1, available at RMD Open online).
Facit-F
LSM changes from baseline and improvements ≥MCID 
in FACIT-F were similar between tofacitinib+MTX and 
tofacitinib monotherapy at all time points (all p>0.05; 
table 1; figure 1D; figure 2D); improvements were compar-
atively lower for ADA+MTX at months 3 and 6, but this did 
not reach statistical significance at both time points. The 
proportions of patients reporting scores ≥normative values 
(≥40.1) were greater with tofacitinib monotherapy versus 
ADA+MTX at month 3 (p<0.05); no statistically significant 
differences were observed between treatment groups when 
considering ≥normative values to be ≥43.5 (online supple-
mentary table S1, available at RMD Open online).
SF-36
Tofacitinib+MTX treatment resulted in greater improve-
ments from baseline in SF-36 PCS versus tofacitinib mono-
therapy, sustained through months 6, 9 and 12 (p<0.05 
for all) (table 1; figure 1E). The proportions of patients 
reporting improvements ≥MCID in SF-36 PCS with tofacitin-
ib+MTX were greater than ADA+MTX at month 3 (p<0.05), 
and versus tofacitinib monotherapy at month 3 (p<0.01) 
and again at month 12 (p<0.05) (figure 2E). No statisti-
cally significant differences in LSM change from baseline 
between treatment arms were reported in SF-36 MCS scores 
at any time point (table 1; figure 1F).
With respect to SF-36 domains, the largest improvements 
were reported at month 3, with continuing incremental 
increases generally observed at months 6, 9 and 12. These 
improvements were generally similar across treatment arms 
at month 6 (online supplementary table S2, available at 
RMD Open online). At month 3, mean SF-36 domain scores 
were numerically higher with tofacitinib monotherapy 
versus both combination therapy arms for the RP and VT 
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Figure 1 PRO scores over time for (A) PtGA, (B) Pain, (C) HAQ-DI, (D) FACIT-F, (E) SF-36 PCS and (F) SF-36 MCS (FAS). PtGA 
and Pain were assessed using 0–100 mm VAS. N numbers evaluable for each outcome may be ≤ those reported for the FAS. 
*p<0.05 tofacitinib+MTX versus tofacitinib monotherapy; **p<0.01 tofacitinib+MTX versus tofacitinib monotherapy; †p<0.05 
ADA+MTX versus tofacitinib monotherapy; ††p<0.01 ADA+MTX versus tofacitinib monotherapy; ‡p<0.05 tofacitinib+MTX versus 
ADA+MTX. ADA, adalimumab; BID, two times per day; FACIT-F, Functional Assessment of Chronic Illness Therapy-Fatigue; 
FAS, full analysis set; HAQ-DI, Health Assessment Questionnaire-Disability Index; LSM, least squares mean; MCID, minimum 
clinically important difference; MCS, mental component summary; MTX, methotrexate; Pain, arthritis pain; PCS, physical 
component summary; PtGA, Patient Global Assessment of Disease Activity; PRO, patient-reported outcome; SE, standard 
error; SF-36, 36-Item Short-Form Health Survey; VAS, visual analogue scale.
domains, and with tofacitinib+MTX versus tofacitinib mono-
therapy and ADA+MTX for the BP domain (figure 4). By 
month 12, mean VT scores approximated age-matched and 
gender-matched norms (differences from the VT normative 
score of 57.2 for tofacitinib monotherapy, tofacitinib+MTX 
and ADA+MTX were –3.5,–2.8 and –1.2, respectively). The 
proportions of patients reporting scores ≥normative values 
and improvements ≥MCID in SF-36 domains are reported 
in online supplementary tables S1 and S3, respectively, avail-
able at RMD Open online.
dIsCussIOn
ORAL Strategy was the first head-to-head, non-inferiority 
RCT directly comparing a Janus kinase inhibitor (tofac-
itinib), as monotherapy or in combination with MTX, with a 
TNFi (ADA) in combination with MTX, in MTX-IR patients 
with RA.
PRO data in ORAL Strategy support the conclusions of 
the primary publication,28 with improvements in all three 
treatment arms reported as early as 3 months after initiation 
(clinically meaningful improvements [≥MCID] at 6 weeks 
in PtGA and Pain), that were generally comparable with 
tofacitinib+MTX and ADA+MTX. Statistically (nominal p 
values) or numerically greater improvements were often, 
but not uniformly, reported with either combination 
therapy compared with tofacitinib monotherapy. Differ-
ences between treatment arms in reported PROs in ORAL 
Strategy are acknowledged to be small. Although it was not 
possible to formally determine whether these differences 
were clinically meaningful, and it must be noted that the 
study was designed to assess non-inferiority of treatment 
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Figure 2 Proportion of patients reporting improvements ≥MCID in (A) PtGA, (B) Pain, (C) HAQ-DI, (D) FACIT-F,  
(E) SF-36 PCS and (F) SF-36 MCS (FAS). MCID: ≥10 mm decrease from baseline in PtGA and Pain; ≥0.22-point decrease 
from baseline in HAQ-DI score; ≥2.5-point increase from baseline in SF-36 PCS and MCS scores; ≥4-point increase from 
baseline in FACIT-F score. *p<0.05 tofacitinib+MTX versus tofacitinib monotherapy; **p<0.01 tofacitinib+MTX versus tofacitinib 
monotherapy; †p<0.05 ADA+MTX versus tofacitinib monotherapy; ‡p<0.05 tofacitinib+MTX versus ADA+MTX; ‡‡p<0.01 
tofacitinib+MTX versus ADA+MTX. ADA, adalimumab; BID, two times per day; FACIT-F, Functional Assessment of Chronic 
Illness Therapy-Fatigue; FAS full analysis set; HAQ-DI, Health Assessment Questionnaire-Disability Index; MCID, minimum 
clinically important difference; MCS, mental component summary; MTX, methotrexate; Pain, arthritis pain; PCS, physical 
component summary; PtGA, Patient Global Assessment of Disease Activity; SF-36, 36-Item Short-Form Health Survey.
arms by the primary clinical endpoint of ACR50 responses 
at month 6, these results are consistent with those of the 
primary outcomes.
Both combination treatments conferred statistically 
significant improvements from baseline versus tofaci-
tinib monotherapy in PtGA and Pain, although this was 
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Figure 3 The proportion of patients reporting (A) Pain scores <20 mm over time, and (B) ≥20%, 30%, 50% or 70% 
improvements in Pain at month 6 (FAS). *p<0.05 tofacitinib+MTX versus tofacitinib monotherapy; **p<0.01 tofacitinib+MTX 
versus tofacitinib monotherapy; †p<0.05 ADA+MTX versus tofacitinib monotherapy; ††p<0.01 ADA+MTX versus tofacitinib 
monotherapy. ADA, adalimumab; BID, two times per day; FAS, full analysis set; MTX, methotrexate; Pain, arthritis pain.
consistently maintained only with tofacitinib+MTX (from 
3 to 12 months). The majority of patients reported clin-
ically meaningful improvements (≥MCID), and while 
these proportions were generally similar between all 
treatment arms at all time points in PtGA and Pain, they 
were numerically greater in Pain in both combination 
arms versus tofacitinib monotherapy from months 3 to 9.
Thresholds of pain improvement used in these anal-
yses were chosen based on recommendations made 
by the Initiative on Methods, Measurement, and Pain 
Assessment in Clinical Trials (IMMPACT) public–
private consortium, whereby a 10%–20% decrease in 
pain intensity was considered ‘minimal’ improvement, 
≥30% was ‘moderate’ and ≥50% ‘substantial’39 40; the 
higher threshold of ≥70% (‘extensive’ improvement) 
was defined in a meta-analysis of seven RCTs.38 In patient 
surveys conducted across America and Europe, daily 
pain was highlighted as a paramount issue in terms of 
disease burden.42 In ORAL Strategy, as many as 45% of 
patients reported Pain scores <20 mm in any treatment 
arm at any time point, and a majority reported ≥20% (all 
>69%) or ≥30% improvements in Pain (all >59%). Both 
combination treatments resulted in significantly greater 
proportions of patients reporting mild pain (Pain scores 
<20 mm) at 3 months, and moderate (≥30%) and exten-
sive (≥70%) improvements in Pain scores at varying 
time points. With discrepancies observed between 
physician-reported and patient-reported disease activity 
largely driven by pain,43 44 it follows that these observa-
tions deserve particular attention.
All treatment arms reported similar improvements 
from baseline in HAQ-DI and FACIT-F at all time points, 
such that the proportions of patients reporting clinically 
meaningful improvements (≥MCID) and scores within 
normative values were generally similar between all treat-
ment arms at all time points. Thus, tofacitinib mono-
therapy was as effective in improving physical function 
and alleviating fatigue as both combination therapies, 
with early improvements in FACIT-F reported in both 
tofacitinib treatment arms.
Diminished HRQoL was evident by the differences 
observed between baseline SF-36 domain scores compared 
with a US age-matched and gender-matched normative 
population. Both combination treatment groups reported 
statistically significant improvements from baseline in 
SF-36 PCS versus tofacitinib monotherapy, evident with 
tofacitinib+MTX at 6, 9 and 12 months. The proportions 
of patients reporting improvements ≥MCID in SF-36 PCS 
generally favoured combination treatments, although 
differences between combination arms (favouring tofac-
itinib+MTX vs ADA+MTX) were also observed at certain 
time points. With regards to domain scores, it is notable that 
the largest improvements were reported at month 3 and 
generally similar across treatment arms, although improve-
ments were numerically higher with tofacitinib mono-
therapy compared with both combination arms at month 
3 for the RP and VT domains, and with tofacitinib+MTX 
compared with tofacitinib monotherapy and ADA+MTX for 
the BP domain.
Recently, treatment with another targeted synthetic 
DMARD, baricitinib+MTX, demonstrated significantly 
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Figure 4 Spydergrams representing mean SF-36 domain scores over time for (A) tofacitinib 5 mg two times per day,  
(B) tofacitinib 5 mg two times per day+MTX and (C) ADA+MTX. The sample sizes indicated represent the number of patients 
who took the SF-36 at that visit. Some domains may have had one to two patients fail to respond. ADA, adalimumab; AG 
norms, age-matched and gender-matched norms; BID, two times per day; BP, Bodily Pain; GH, General Health; MH, Mental 
Health; MTX, methotrexate; PF, Physical Functioning; RE, Role Emotional; RP, Role Physical; SF, Social Functioning; SF-36, 36-
Item Short-Form Health Survey; VT, Vitality.
greater improvements in PROs including physical func-
tion, pain, fatigue and HRQoL, compared with placebo 
or ADA+MTX, in the head-to-head RA-BEAM trial in 
MTX-IR patients with RA.45 Baricitinib monotherapy was 
not evaluated in RA-BEAM. Taken together, ORAL Stan-
dard, ORAL Strategy and RA-BEAM provide consistent 
support for the benefits of a targeted synthetic DMARD 
(tofacitinib or baricitinib) and csDMARD combination for 
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the treatment of RA, with at least similar efficacy to a TNFi 
(such as ADA)+MTX.
The limitations of ORAL Strategy are discussed in detail 
in the primary publication.28 Of note, although TNFi share 
a common mechanism of action, the generalisability of 
observations in patients receiving ADA+MTX in ORAL 
Strategy to other TNFi is limited. In this analysis, nominal 
p values were not controlled for multiple comparisons, so 
must be interpreted with caution. Data were not collected 
at time points earlier than 6 weeks, so an evaluation of early 
PRO benefits, as previously reported with tofacitinib mono-
therapy and combination therapy versus placebo, is not 
possible.
In addition, the majority of patients were enrolled from 
countries or regions with low accessibility to bDMARDs 
and RCTs, and regional differences may therefore 
occur in outcomes. Further research into reported PRO 
results across different regions is warranted to determine 
approaches to best meet local patient needs.
In conclusion, treatment with tofacitinib+MTX, 
ADA+MTX and tofacitinib monotherapy resulted in clin-
ically meaningful improvements (≥MCID) and scores 
approaching normative values across a broad range of 
PROs in MTX-IR patients with RA. These improvements 
were generally, but not uniformly, greater with both 
combination arms than with monotherapy; however, it 
was not possible to determine the clinical value of these 
differences between treatment groups. Primary effi-
cacy data from ORAL Strategy supported a preference 
for adding tofacitinib to MTX rather than switching to 
tofacitinib monotherapy,28 which has shown efficacy 
versus placebo.22 These PRO data suggest that in patients 
without sufficient responses to, or who are intolerant to, 
MTX, tofacitinib monotherapy can be an effective alter-
native treatment. Future research to identify subsets of 
patients that consistently show improvements in all, or 
specific, PROs, warrants consideration, to determine 
tailored treatment approaches for MTX-IR patients with 
RA.
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